Heme cascade-triggered nanovesicles for myocardial ischemic core delivery - PubMed
8 hours ago
- #Targeted Drug Delivery
- #Heme-responsive Nanovesicles
- #Myocardial Repair
- Designed the first heme-responsive nanovesicle (DecAS-PC@NM) for targeted therapy in myocardial ischemia-reperfusion injury (MIRI) by leveraging the heme cascade.
- Mechanism involves heme activating artemisinin-modified phospholipid (A-PC) to generate ROS, oxidizing thioether in S-PC, causing a hydrophilic-to-hydrophobic transition and vesicle disassembly.
- Enhanced targeting via co-assembly with neutrophil membranes to improve chemotaxis toward inflammatory sites.
- Demonstrated unique heme responsiveness in vitro and effective ischemic core targeting with therapeutic benefits in vivo.
- The heme-triggered phospholipid cascade offers a promising new strategy for treating MIRI, addressing current challenges in targeted drug delivery.